Bile acid metabolites in serum: Intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Steiner, Carine ^a,b   Othman, Alaa ^a,b   Saely, Christoph H ^c,d,e   Rein, Philipp ^c,d,e   Drexel, Heinz ^c,d,e,f   von Eckardstein, Arnold ^a,b   Rentsch, Katharina M ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^d Academic Teaching Hospital Feldkirch   (Austria)

^e PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7ALPHA HYDROXYCHOLEST 4 EN 3 ONE; BILE ACID; BILE ACID CONJUGATE; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 7 ALPHA HYDROXY 4 CHOLESTEN 3 ONE; 7 ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; CHOLEST 4 EN 3 ONE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CIRCADIAN RHYTHM; CONTROLLED STUDY; COSMOLOGICAL PHENOMENA; DAYTIME; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; FOOD INTAKE; HUMAN; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METABOLITE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRINCIPAL COMPONENT ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; EATING; METABOLISM; MIDDLE AGED; STATISTICAL MODEL; TIME;

ADULT; AGED; BILE ACIDS AND SALTS; CASE-CONTROL STUDIES; CHOLESTENONES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; EATING; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; TIME FACTORS;

EID: 81155153943     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025006     Document Type: Article

References (70)

1. Alberti KG, Zimmet PZ, (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421.
3. Alberti KG, Zimmet P, Shaw J, (2005) The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062.
4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
5. Olefsky JM, Glass CK, (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219-246.
6. Cani PD, Delzenne NM, (2009) The Role of the Gut Microbiota in Energy Metabolism and Metabolic Disease. Current Pharmaceutical Design 15: 1546-1558.
7. Staels B, Handelsman Y, Fonseca V, (2010) Bile acid sequestrants for lipid and glucose control. Curr Diab Rep 10: 70-77.
8. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K, (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7: 678-693.
9. Russell DW, (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72: 137-174.
10. Sauter G, Berr F, Beuers U, Fischer S, Paumgartner G, (1996) Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 24: 123-126.
11. Hofmann AF, Hagey LR, (2008) Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65: 2461-2483.
12. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, et al. (1999) Identification of a nuclear receptor for bile acids. Science 284: 1362-1365.
13. Wang H, Chen J, Hollister K, Sowers LC, Forman BM, (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3: 543-553.
14. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284: 1365-1368.
15. Angelin B, Einarsson K, Hellstrom K, Leijd B, (1978) Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J Lipid Res 19: 1017-1024.
16. Crouse JR 3rd, (1987) Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 83: 243-248.
17. Shepherd J, Packard CJ, Morgan HG, Third JL, Stewart JM, et al. (1979) The effects of cholestyramine on high density lipoprotein metabolism. Atherosclerosis 33: 433-444.
18. Lin Y, Havinga R, Schippers IJ, Verkade HJ, Vonk RJ, et al. (1996) Characterization of the inhibitory effects of bile acids on very-low-density lipoprotein secretion by rat hepatocytes in primary culture. Biochem J 316 (Pt 2): 531-538.
19. Lin Y, Havinga R, Verkade HJ, Moshage H, Slooff MJ, et al. (1996) bile acids suppress the secretion of very-low-density lipoprotein by human hepatocytes in primary culture. Hepatology 23: 218-228.
20. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, et al. (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102: 731-744.
21. Lambert G, Amar MJ, Guo G, Brewer HB Jr, Gonzalez FJ, et al. (2003) The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 278: 2563-2570.
22. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, et al. (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113: 1408-1418.
23. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA, (2004) Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 18: 157-169.
24. Sirvent A, Claudel T, Martin G, Brozek J, Kosykh V, et al. (2004) The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett 566: 173-177.
25. Anisfeld AM, Kast-Woelbern HR, Meyer ME, Jones SA, Zhang Y, et al. (2003) Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. J Biol Chem 278: 20420-20428.
26. Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, et al. (2001) Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 15: 1720-1728.
27. Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, et al. (2006) Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta 1761: 1401-1409.
28. Zhang Y, Wang X, Vales C, Lee FY, Lee H, et al. (2006) FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler Thromb Vasc Biol 26: 2316-2321.
29. Hanniman EA, Lambert G, McCarthy TC, Sinal CJ, (2005) Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J Lipid Res 46: 2595-2604.
30. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, et al. (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 103: 1006-1011.
31. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk T, Grefhorst A, et al. (2005) Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett 579: 4076-4080.
32. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, et al. (2006) The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281: 11039-11049.
33. Ma K, Saha PK, Chan L, Moore DD, (2006) Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116: 1102-1109.
34. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, et al. (2005) Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146: 984-991.
35. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, et al. (2004) Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 279: 23158-23165.
36. De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, et al. (2003) Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 278: 39124-39132.
37. Hassan AS, Subbiah MT, Thiebert P, (1980) Specific changes of bile acid metabolism in spontaneously diabetic Wistar rats. Proc Soc Exp Biol Med 164: 449-452.
38. Hassan AS, Hedeen K, Subbiah MT, (1981) Effect of maternal diabetes on fetal bile acid metabolism in the rat. Biochem Med 25: 168-173.
39. van Waarde WM, Verkade HJ, Wolters H, Havinga R, Baller J, et al. (2002) Differential effects of streptozotocin-induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology 122: 1842-1852.
40. Uchida K, Makino S, Akiyoshi T, (1985) Altered bile acid metabolism in nonobese, spontaneously diabetic (NOD) mice. Diabetes 34: 79-83.
41. Bennion LJ, Grundy SM, (1977) Effects of diabetes mellitus on cholesterol metabolism in man. N Engl J Med 296: 1365-1371.
42. Abrams JJ, Ginsberg H, Grundy SM, (1982) Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 31: 903-910.
43. Andersen E, Hellstrom P, Hellstrom K, (1987) Cholesterol biosynthesis in nonketotic diabetics before and during insulin therapy. Diabetes Res Clin Pract 3: 207-214.
44. Noshiro M, Nishimoto M, Okuda K, (1990) Rat liver cholesterol 7 alpha-hydroxylase. Pretranslational regulation for circadian rhythm. J Biol Chem 265: 10036-10041.
45. Galman C, Angelin B, Rudling M, (2005) Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 129: 1445-1453.
46. Duane WC, Levitt DG, Mueller SM, Behrens JC, (1983) Regulation of bile acid synthesis in man. Presence of a diurnal rhythm. J Clin Invest 72: 1930-1936.
47. Saely CH, Vonbank A, Rein P, Woess M, Beer S, et al. (2008) Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. Clin Chim Acta 397: 82-86.
48. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
49. Steiner C, von Eckardstein A, Rentsch KM, (2010) Quantification of the 15 major human bile acids and their precursor 7alpha-hydroxy-4-cholesten-3-one in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878: 2870-2880.
50. Suhre K, Meisinger C, Doring A, Altmaier E, Belcredi P, et al. (2010) Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting. Plos One 5.
51. Zhao XJ, Fritsche J, Wang JS, Chen J, Rittig K, et al. (2010) Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 6: 362-374.
52. Angelin B, Bjorkhem I, (1977) Postprandial serum bile acids in healthy man. Evidence for differences in absorptive pattern between individual bile acids. Gut 18: 606-609.
53. Schalm SW, LaRusso NF, Hofmann AF, Hoffman NE, van Berge-Henegouwen GP, et al. (1978) Diurnal serum levels of primary conjugated bile acids. Assessment by specific radioimmunoassays for conjugates of cholic and chenodeoxycholic acid. Gut 19: 1006-1014.
54. Hepner GW, Demers LM, (1977) Dynamics of the enterohepatic circulation of the glycine conjugates of cholic, chenodeoxycholic, deoxycholic, and sulfolithocholic acid in man. Gastroenterology 72: 499-501.
55. Setchell KD, Lawson AM, Blackstock EJ, Murphy GM, (1982) Diurnal changes in serum unconjugated bile acids in normal man. Gut 23: 637-642.
56. Pooler PA, Duane WC, (1988) Effects of bile acid administration on bile acid synthesis and its circadian rhythm in man. Hepatology 8: 1140-1146.
57. Kovar J, Lenicek M, Zimolova M, Vitek L, Jirsa M, et al. (2010) Regulation of diurnal variation of cholesterol 7alpha-hydroxylase (CYP7A1) activity in healthy subjects. Physiol Res 59: 233-238.
58. Chiang JY, (2004) Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J Hepatol 40: 539-551.
59. Engelking LR, Dasher CA, Hirschowitz BI, (1980) Within-day fluctuations in serum bile-acid concentrations among normal control subjects and patients with hepatic disease. Am J Clin Pathol 73: 196-201.
60. Brufau G, Stellaard F, Prado K, Bloks VW, Jonkers E, et al. (2010) Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52 (4): 1455-64.
61. Brufau G, Bahr MJ, Staels B, Claudel T, Ockenga, et al. (2010) Plasma bile acids are not associated with energy metabolism in humans. Nutr Metab (Lond) 3;7: 73.
62. Staels B, Kuipers F, (2007) Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67: 1383-1392.
63. Hageman J, Herrema H, Groen AK, Kuipers F, (2010) A role of the bile salt receptor FXR in atherosclerosis. Arterioscler Thromb Vasc Biol 30: 1519-1528.
64. Angelin B, Hershon KS, Brunzell JD, (1987) bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia. Proc Natl Acad Sci U S A 84: 5434-5438.
65. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B, (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89: 147-191.
66. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K, (2010) The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol.
67. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, et al. (2009) Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17 (9): 1671-7.
68. Prawitt J, Abdelkarim M, Stroeve JH, Popescu I, Duez H, et al. (2011) Farnesoid x receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60 (7): 1861-71.
69. Abdelkarim M, Caron S, Duhem C, Prawitt J, Dumont J, et al. (2010) The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem 19;285 (47): 36759-67.
70. Castro J, Amigo L, Miquel JF, Galman C, Crovari F, et al. (2007) Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology 45: 1261-1266.